



# Q-LINE BIOTECH LIMITED

## THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON SME PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE EMERGE")

Our Company was originally incorporated as "POCT Services Private Limited" on November 10, 2010 as a Private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 10, 2010 issued by the Assistant Registrar of Companies, Uttar Pradesh and Uttarakhand bearing CIN U74120UP2010PTC042528. Subsequently, pursuant to a special resolution passed by our shareholders in the Extra-Ordinary General Meeting held on June 12, 2021, the name of our Company was changed to "Q-Line Biotech Private Limited and a fresh certificate of incorporation pursuant to change of name dated July 23, 2021 was issued to our Company by the Registrar of Companies, Kanpur. Further, pursuant to a special resolution passed by our Shareholders in the Extra-Ordinary General Meeting held on February 19, 2025, our Company was converted from a private limited company to public limited company and consequently the name of our Company was changed to "Q-Line Biotech Limited", and a fresh certificate of incorporation dated March 08, 2025 was issued to our Company by the Registrar of Companies, Central Processing Centre. The CIN of the Company is U74120UP2010PLC042528. For further details of incorporation, change of registered office of our Company, please refer to chapter titled "History and Corporate Structure" beginning on page 152 of the Prospectus.

**Registered Office:** 298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, India, 226012  
**Tel.:** +91 522-2435570, **E-mail:** compliance@qlinebiotech.com ; **Website:** www.qlinebiotech.com  
**CIN:** U74120UP2010PLC042528 ; **Contact Person:** Akhand Pratap Singh, Company Secretary & Compliance Officer

### OUR PROMOTERS: SAURABH GARG, AMITA GARG, AYUSH GARG, AJAY KUMAR MAHANTY AND ABHAY AGRAWAL

Our Company has filed the Prospectus dated May 26, 2026 with ROC and thereafter with SEBI and the stock exchange and Equity Shares are proposed to be listed on SME Platform of NSE (NSE Emerge) on May 29, 2026.

**"THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF NSE (NSE EMERGE)."**

### BRIEF DESCRIPTION OF THE BUSINESS OF THE COMPANY

We are engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. Our company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majority to diagnostic service providers, hospitals and medical colleges. The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of our Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

### BASIS OF ALLOTMENT

INITIAL PUBLIC OFFER OF UPTO 62,53,200 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE "EQUITY SHARES") OF Q-LINE BIOTECH LIMITED ("OUR COMPANY" OR "QLBL" OR "THE ISSUER") AT AN ISSUE PRICE OF ₹ 343 PER EQUITY SHARE (INCLUDING SHARE PREMIUM OF ₹333 PER EQUITY SHARE) FOR CASH, AGGREGATING UP TO ₹ 21,448.48 LAKHS ("PUBLIC ISSUE") OUT OF WHICH 3,13,200 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ 343 PER EQUITY SHARE FOR CASH, AGGREGATING ₹ 1,074.28 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 59,40,000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ 343 PER EQUITY SHARE FOR CASH, AGGREGATING UPTO ₹ 20,374.20 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 26.81 % AND 25.46 % RESPECTIVELY OF THE POST- ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE FACE VALUE OF THE EQUITY SHARE IS RS. 10/- AND ISSUE PRICE IS RS. 343/- EACH. THE ISSUE PRICE IS 34.30 TIMES OF THE FACE VALUE OF THE EQUITY SHARE  
 ANCHOR INVESTOR ISSUE PRICE: RS. 343/- PER EQUITY SHARE.  
 THE ISSUE PRICE IS 34.30 TIMES OF THE FACE VALUE

### BID/ ISSUE PERIOD

**ANCHOR INVESTOR BIDDING DATE: WEDNESDAY, MAY 20, 2026**

**BID/ ISSUE OPENED ON: THURSDAY, MAY 21, 2026**

**BID/ ISSUE CLOSED ON: MONDAY, MAY 25, 2026**

### RISKS TO INVESTORS:

- Any disruption, stoppage, slowdown or shutdown in our manufacturing facilities or process or research and development activities could adversely affect our business, financial condition, cash flows and results of operations.
- Any delay, interruption or reduction in the supply of our raw materials, trade goods from our suppliers and manufacturers both domestic and imported, or an increase in the costs of such raw materials, trade goods may adversely impact the pricing and supply of our products and have an adverse effect on our business, financial condition, cash flows and results of operations.
- Our business is dependent on the sale of our products through distributors which also include our group entity POCT services. The loss of any of these distributors or third parties for any reason may adversely affect the marketing and distribution of our products and could negatively impact our business, results of operations, financial conditions and cash flows.
- We are dependent on certain key suppliers to procure a significant portion of our Raw material for production of reagents and for traded machines. Any denial of supplies or loss of the relationship with them could result in disruption in our operations, which could have an adverse effect on our business, financial condition, results of operations and cash flows.
- We are required to obtain, maintain or renew our statutory and regulatory approvals, licenses, and registrations to operate our business.
- For manufacturing of our machines and reagents, we are dependent on the agreement with the European companies, any failure to renew the agreement or entering into the agreement on the terms which are not favourable for us may impact our business operations, financial condition and cash flows.
- Our erstwhile associate company i.e. POCT Science House Private Limited and our promoters namely Saurabh Garg and Amita Garg have been subject to search and seizure operations by the Income-tax Department and any adverse outcome of these proceedings may adversely affect our financial condition.
- Our operations are concentrated in North India, and any loss of business in such region could have an adverse effect on our business, results of operations and financial condition.
- Our Company requires a significant amount of working capital for continuing growth. Our inability to meet our working capital requirements may adversely affect our results of operations.
- We are subject to risks arising from exchange rate fluctuations.
- The BRLMs associated with the Issue have handled 79 Public Issues in the past three years, out of which 8 issues were closed below the Issue Price on listing date.

- Average cost of acquisition of Equity Shares held by the Promoters is

Sr. No.	Name of Promoter	No. of Shares held	Average Cost of Acquisition (in ₹)
1.	Saurabh Garg	1,01,91,000	0.04
2.	Amita Garg	39,37,480	0.00
3.	Ayush Garg	31,500	0.00
4.	Ajay Kumar Mahanty	7,50,000	18.34
5.	Abhay Agrawal	7,56,010	0.00

- The Price/ Earnings ratio based on Diluted EPS for Fiscal 2025 for the company at the upper end (₹343) of the Price Band is 11.98
- Weighted Average Return on Net worth for Fiscals 2025, 2024 and 2023 is 23.17%.
- The Weighted average cost of acquisition of all Equity Shares transacted in the last one year, 18 months and three years from the date of Prospectus is as given below:

Period	Weighted Average Cost of Acquisition (in Rs.)	Cap Price (₹343) is 'X' times the Weighted Average Cost of Acquisition	Range of acquisition price: Lowest Price – Highest Price (in Rs.)
Last one year, Last 18 Months, three years preceding the date of the Prospectus	17.88	19.18	0-343

- The Weighted average cost of acquisition compared to Floor Price and Cap Price.

Types of transactions	Weighted average cost of acquisition (₹ per Equity Shares of face value of Rs. 10/-)	Floor price (i.e. ₹ 326)	Cap price (i.e. ₹ 343)
Weighted average cost of acquisition of primary / new Issue	NA^	NA^	NA^
Weighted average cost of acquisition for secondary sale / acquisition	NA^^	NA^^	NA^^
Weighted average cost of acquisition of primary issuances/ secondary transactions	17.89	18.22	19.17

#### Note:

^There were no primary/ new issue of shares (equity/ convertible securities) in last 18 months from the date of the Prospectus, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of 30 days ("Primary Issue").

^^There were no secondary transactions in last 18 months from the date of the Prospectus, where either acquisition or sale is equal to or more than 5% of the fully diluted paid up share capital of the Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days ("Secondary Transaction").

### PROPOSED LISTING: MAY 29, 2026\*

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), 40% of the Anchor Investor Portion shall be reserved for, (i) 33.33% shall be available for allocation to domestic Mutual Funds, and (ii) 6.67% for life insurance companies and pension funds, subject to valid Bids being received from domestic Mutual Funds, life insurance companies and pension funds at or above the Anchor Investor Allocation Price. In the event of under-subscription in (ii) above, the allocation may be made to domestic Mutual Funds in accordance with the SEBI ICDR Regulations. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders (1/3rd of the portion available to NIBs shall be reserved for applicants with an application size of more than 2 lots and upto such lots equivalent to not more than ₹ 10.00 Lakhs and 2/3rd of the portion available to NIBs shall be reserved for applicants with an application size of more than ₹ 10.00 Lakhs and the unsubscribed portion in either of the sub categories, could be allocated to applicants in the other sub-category of NIBs) and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of Individual Investors using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 341 of the Prospectus.

The investors are advised to refer to the Prospectus for the full text of the Disclaimer clause pertaining to NSE. For the purpose of this Issue, the designated Stock Exchange will be the National Stock Exchange of India Limited. The trading is proposed to be commenced on May 29, 2026 \*

\*Subject to the receipt of listing and trading approval from the NSE ("NSE EMERGE").

### SUBSCRIPTION DETAILS

The bidding for Anchor Investors opened and closed on Wednesday, May 20, 2026. The Company received 18 Anchor Investors applications for 20,43,600 Equity Shares. The Anchor Investor Allocation price was finalized at ₹343/- per Equity Share. A total of 17,81,200 Equity Shares were allotted under the Anchor Investors portion aggregating to ₹ 61,09,51,600.00

The Issue (excluding Anchor Investors Portion) received 2,36,894 Applications for 42,80,91,600 Equity Shares (after considering invalid bids, Other than RC10 Transaction declined by Investors, RC10 Mandate not accepted by Investors and Withdrawal/ Cancelled Bids reported by SCSB and rejections) resulting 95.73 times subscription (including reserved portion of market maker and excluding anchor investor portion). The details of the Applications received in the Issue from various categories are as under (before rejections):

#### Detail of the Applications Received (excluding Anchor Investors Portion):

Sr. No.	Category	Number of Applications	No. of Equity Shares applied	Equity Shares Reserved as per Prospectus	No. of times Subscribed	Amount (Rs.)
1.	Individual Investors	1,86,599	14,92,79,200	20,79,200	71.80	51,19,89,82,000
2.	Non-institutional Investors (More than 2 lots and up to ₹10 lakhs)	18,802	2,44,19,600	2,97,200	82.17	8,37,28,52,000
3.	Non-institutional Investors (above ₹10 lakhs)	31,365	10,70,06,400	5,94,400	180.02	36,70,29,09,200
4.	Qualified Institutional Bidders (excluding Anchors Investors)	127	14,70,73,200	11,88,000	123.80	50,44,61,07,600
5.	Market Maker	1	3,13,200	3,13,200	1.00	10,74,27,600
	<b>Total</b>	<b>2,36,894</b>	<b>42,80,91,600</b>	<b>44,72,000</b>	<b>95.73</b>	<b>1,46,82,82,78,400</b>

#### Final Demand:

A summary of the final demand as per NSE as on the Bid/ Issue Closing Date at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Share Total	Cumulative % of Total
1	326	3,23,200	0.07%	3,23,200.00	0.07%
2	327	22,000	0.00%	3,45,200.00	0.08%
3	328	4,800	0.00%	3,50,000.00	0.08%
4	329	6,800	0.00%	3,56,800.00	0.08%
5	330	48,400	0.01%	4,05,200.00	0.09%

6	331	1,600	0.00%	4,06,800.00	0.09%
7	332	4,000	0.00%	4,10,800.00	0.09%
8	333	17,600	0.00%	4,28,400.00	0.10%
9	334	8,400	0.00%	4,36,800.00	0.10%
10	335	42,400	0.01%	4,79,200.00	0.11%
11	336	7,200	0.00%	4,86,400.00	0.11%
12	337	800	0.00%	4,87,200.00	0.11%
13	338	10,000	0.00%	4,97,200.00	0.11%
14	339	10,800	0.00%	5,08,000.00	0.11%
15	340	48,800	0.01%	5,56,800.00	0.12%
16	341	84,800	0.02%	6,41,600.00	0.14%
17	342	1,75,200	0.04%	8,16,800.00	0.18%
18	343	44,75,67,200	99.82%	44,83,84,000.00	100.00%
	<b>Total</b>	<b>44,83,84,000</b>	<b>100.00%</b>		

The Basis of Allotment was finalized in consultation with the designated Stock Exchange, being National Stock Exchange of India Limited ("NSE EMERGE") on May 26, 2026.

#### 1) Allotment to Individual Investors (After Rejections):

The Basis of Allotment to the Individual Investors, who have Bid at or above the Issue Price of ₹ 343/- per Equity Share, was finalized in consultation with NSE. The category has been subscribed to the extent of 70.27 times i.e. for 14,61,12,800 Equity Shares. The total number of Equity Shares Allotted in this category is 20,79,200 Equity to 2,599 successful applicants. The details of the Basis of Allotment of the said category are as under:

No. of Shares Applied for (Category wise)	No. of Applications Received	% of Total	Total No. of Shares Applied	% to Total	No. of Equity Shares Allotted per Applicant	Ratio	Total No. of shares allocated/ allotted
800	182641	100.00	14,61,12,800	100.00	800	2599:182641	20,79,200

Continued on next page

Continued from previous page

**2) Allotment to Non-Institutional Investors (More than 2 lots and up to ₹ 10,00,000) (After Rejections):**

The Basis of Allotment to the Non-Institutional Investors, who have bid at the Issue Price of ₹ 343/- or above per Equity Share was finalized in consultation with NSE. The category has been subscribed to the extent of 80.67 times i.e. for 2,39,74,800 Equity Shares (after rejection). The total number of Equity Shares Allotted in this category is 2,97,200 Equity Shares to 247 successful applicants. The details of the Basis of Allotment of the said category are as under:

No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No of equity shares	Ratio of allottees to applicants	Total No. of shares allocated/allotted
1200	16,550	89.67	1,98,60,000	82.83	2,66,507.37	222:16,550	2,66,400
1600	727	3.93	11,63,200	4.85	11,707.00	9:727	10,800
2000	283	1.53	5,66,000	2.36	4,557.20	4:283	4,800
2400	308	1.66	7,39,200	3.08	4,959.77	4:308	4,800
2800	588	3.18	16,46,400	6.86	9,468.66	8:588	9,600
2 out of 25 Successful Allottees from Serial no 2-5 will get Additional 1 lot of 400 shares						2:25	800
<b>TOTAL</b>	<b>18,456</b>	<b>100.00</b>	<b>2,39,74,800</b>	<b>100.00</b>	<b>2,97,200</b>		<b>2,97,200</b>

**3) Allotment to Non-Institutional Investors (More than ₹ 10,00,000)**

The Basis of Allotment to the Non-Institutional Investors, who have bid at the Issue Price of ₹ 343/- or above per Equity Share was finalized in consultation with NSE. The category has been subscribed to the extent of 178.11 times i.e. for 10,58,66,000 Equity Shares (after rejection). The total number of Equity Shares Allotted in this category is 5,94,400 Equity to 495 successful applicants. The details of the Basis of Allotment of the said category are as under:

No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	Proportionate shares available	Ratio of allottees to applicants	Total No. of shares allocated/allotted
3,200	29,597	95.05	9,47,10,400	89.46	5,65,019.81	471:29597	5,65,200
3,600	498	1.59	17,92,800	1.69	9,507.04	8:498	9,600
4,000	273	0.87	10,92,000	1.03	5,211.69	4:273	4,800
4,400	126	0.40	5,54,400	0.52	2,405.40	1:63	2,400
4,800	62	0.19	2,97,600	0.28	1,183.61	1:62	1,200
5,200	85	0.27	4,42,000	0.41	1,622.69	1:85	1,200
5,600	55	0.17	3,08,000	0.29	1,049.97	1:55	1,200
6,000	55	0.17	3,30,000	0.31	1,049.97	1:55	1,200
6,400	81	0.26	5,18,400	0.48	1,546.33	1:81	1,200
7,200	38	0.12	2,73,600	0.25	725.44	1:38	1,200
11,200	4	0.01	44,800	0.04	76.36	0:0	-
15,200	1	0.00	15,200	0.01	19.09	0:0	-
20,400	1	0.00	20,400	0.01	19.09	0:0	-
29,200	4	0.01	1,16,800	0.11	76.36	0:0	-
54,000	1	0.00	54,000	0.05	19.09	0:0	-
1,46,000	1	0.00	1,46,000	0.13	19.09	0:0	-
4 out of 266 un-successful Allottees from Serial no 10 & 12 to73 will get Additional 1 lot of 1200 shares						4:266	4800
1 out of 495 successful Allottees will get Additional 1 lot of 400 shares						1:495	400

**4) Allotment to Market Maker:** The Basis of Allotment to Market Maker who have bid at Issue Price of ₹ 343/- per Equity Shares or above, was finalized in consultation with NSE. The category was subscribed by 1.00 times i.e. for 3,13,200 Equity shares the total number of shares allotted in this category is 3,13,200 Equity Shares. The category wise details of the Basis of Allotment are as under:

No. of Shares Applied for (Category wise)	No. of Applications received	% to total	Total No. of Equity Shares applied in this Category	% of total	No. of Equity Shares allocated/ allotted per Applicant	Ratio	Total No. of shares allocated/allotted
3,13,200	1	100.00	3,13,200	100.00	3,13,200	1:1	<b>3,13,200</b>

**5) Allotment to QIBs excluding Anchor Investors (After Rejections):**

The Basis of Allotment to QIBs, who have bid at Issue Price of ₹ 343/- per Equity Shares or above, was finalized in consultation with NSE. The category was subscribed by 123.80 times i.e. for 14,70,73,200 Equity shares. As per the SEBI Regulations, 5% of Net QIB portion was reserved for mutual funds i.e. 59,200 Equity Shares and other QIBs and unsatisfied demand of Mutual Funds were allotted the remaining available Equity Shares i.e. 11,28,800 Equity Shares on a proportionate basis. The total number of shares allotted in this category is 11,88,000 Equity Shares to 115 successful applicants. The category wise details of the Basis of Allotment are as under:

Category	FI'S/BANK'S	MF'S	IC'S	NBFC'S	AIF	FPC/FII	Others	Total
<b>QIB</b>	2,02,000	79,600	4,400	1,53,600	3,78,000	1,58,800	2,11,600	<b>11,88,000</b>

**6) Allotment to Anchor Investors (After Rejections):**

The Company in consultation with the BRLM has allocated 17,81,200 Equity Shares to 18 Anchor Investors at the Anchor Investor Issue Price of ₹ 343/- per Equity Shares in accordance with the SEBI (ICDR) Regulations. This represents upto 60% of the QIB Category.

CATEGORY	FIS/BANKS	MF'S	IC'S	NBFC'S	AIF	FPI/FPC	VC'S	TOTAL
<b>ANCHOR</b>	29,200	2,91,600	-	29,200	12,00,400	2,30,800	-	<b>17,81,200</b>

The Board of Directors of our Company at its meeting held on May 26, 2026 has taken on record the basis of allotment of Equity Shares approved by the designated Stock Exchange, being NSE and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Refund Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSBs have been dispatched / mailed for unblocking of funds and transfer to the Public Issue Account on or before May 27, 2026. In case the same is not received within ten days, Investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on May 27, 2026 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from NSE and the trading of the Equity Shares is expected to commence trading on May 29, 2026.

**Note:** All capitalized terms used and not defined herein shall have the respective meanings assigned to them in the Prospectus dated May 26, 2026 filed with the Registrar of Companies, Uttar Pradesh ("RoC").

**INVESTORS, PLEASE NOTE**

The details of the allotment made has been hosted on the website of the Registrar to the Issue, Purva Sharegistry (India) Private Limited

**TRACK RECORD OF BOOK RUNNING LEAD MANAGER:** The BRLMs associated with the Issue have handled 79 Public Issues in the past three years, out of which 8 issues were closed below the Issue Price on listing date:

Name of BRLM	Total Issue		Issue closed below IPO Price on listing date
	Mainboard	SME	
Hem Securities Limited	2	62	4 (SME)
Share India Capital Services Private Limited	-	14	4
Common*	-	1	-
<b>Total</b>	<b>2</b>	<b>77</b>	<b>8</b>

\* Issue in which both BRLMs were involved.

All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/ Sole Bidder Serial number of the ASBA form, number of Equity Shares bid for, Bidder DP ID, Client ID, PAN, date of submission of the Bid cum Application Form, address of the Bidder, the name and address of the Designated Intermediary where the Bid cum Application Form was submitted by the Bidder and copy of the Acknowledgment Slip received from the Designated Intermediary and payment details at the address given below:

	<p><b>Purva Sharegistry (India) Private Limited</b> Address: 9, Shiv Shakti Industrial Estate, J.R. Boricha Marg Lower Parel (East), Mumbai, Maharashtra, India, 400011 Tel. No.: 91 22 41343255/41343271 Email: newissue@purvashare.com Website: www.purvashare.com Contact Person: Deepali Gaonkar SEBI Registration No.: INR000001112</p>
---	--

On behalf of Board of Directors  
Q-Line Biotech Limited  
Sd/-  
Akhand Pratap Singh  
Company Secretary and Compliance Officer

Place: Lucknow

Date: May 27, 2026

**THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF Q-LINE BIOTECH LIMITED**

**Disclaimer:** Q-Line Biotech Limited has filed the Prospectus with the RoC on May 26, 2026 and thereafter with SEBI and the Stock Exchange. The Prospectus is available on the website of the BRLMs, Hem Securities Limited and Share India Capital Services Private Limited at www.hemsecurities.com and www.shareindia.com and the Company at: www.qlinebiotech.com and shall also be available on the website of the NSE and SEBI. Investors should note that investment in Equity Shares involves a high degree of risk and for details relating to the same, please see "Risk Factors" beginning on page 20 of the Prospectus. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being Issued and sold outside the United States in 'offshore transactions' in reliance on Regulation under the Securities Act and the applicable laws of each jurisdiction where such Issues and sales are made. There will be no public Issuing in the United States.

Part - 2 Size : 33x24